Evaluation of RF300 for Leukoreduction of Red Blood Cells / 대한수혈학회지
Korean Journal of Blood Transfusion
;
: 13-19, 2012.
Article
Dans Anglais
| WPRIM
| ID: wpr-76698
ABSTRACT
BACKGROUND:
Use of universal leukoreduction for prevention of leukocyte associated transfusion reactions is common practice in many countries. This study was conducted in order to evaluate the performance of a newly developed leukoreduction filter for red blood cells (RBCs), the RF300 (Kolon Industries, Inc, Gumi, Korea).METHODS:
Filtration time, RBC recovery, residual leukocyte count, and leukocyte removal rate were evaluated. To assess the quality of RBCs after filtration, percent hemolysis was monitored for a period of 21 days. Performance of the RF300 (N=78) was compared with that of the Bio-R O2 plus (Fresenius, Hamburg, Germany), the Pall Purecell RC (Pall Co., Washington, USA), and the Sepacell R-500N (Asahi, Tokyo, Japan).RESULTS:
The shortest filtration time was observed using the RF300 (P<0.05). Using the RF300, recovery of RBC was 96.5%, which was higher than that of two filters (P<0.05). Mean residual leukocyte count was 0.26x10(6)/unit, with a leukocyte removal rate of 3 log. Using the RF300, mean percent hemolysis was 0.32% at day 21, which was comparable with that of two filters, but lower than that of one filter (P<0.05).CONCLUSION:
The RF300 meets all established quality requirements for conduct of safe and effective leukoreduction of RBCs.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Tokyo
/
Incompatibilité sanguine
/
Washington
/
Collodion
/
Érythrocytes
/
Filtration
/
Hémolyse
/
Numération des leucocytes
/
Leucocytes
Pays comme sujet:
Amérique du Nord
/
Asie
langue:
Anglais
Texte intégral:
Korean Journal of Blood Transfusion
Année:
2012
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS